Topoisomerase I protein expression in primary colorectal cancer and recurrences after 5-FU-based adjuvant chemotherapy

Journal of Cancer Research and Clinical Oncology

Volumn 133, Issue 12, 2007, Pages 1011-1015

  Gouveris, P ^a   Lazaris, A C ^a   Papathomas, T G ^a,c   Nonni, A ^a   Kyriakou, V ^b   Delladetsima, J ^b   Patsouris, E S ^a   Tsavaris, N ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b KAT HOSPITAL   (Greece)

^c NONE   (Greece)

Author keywords

5 FU; Chemotherapy; Primary colorectal cancer; Recurrences; Topoisomerase I protein expression

Indexed keywords

CAMPTOTHECIN; DNA TOPOISOMERASE; FLUOROURACIL;

AGE DISTRIBUTION; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER PATIENT; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURGERY; CELL DIFFERENTIATION; CLINICAL ARTICLE; COLORECTAL CARCINOMA; COLORECTAL SURGERY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE FREE INTERVAL; DRUG SENSITIVITY; FISHER EXACT TEST; HUMAN; HUMAN TISSUE; PHENOTYPE; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT CANCER; SEX DIFFERENCE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

AGE FACTORS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DNA TOPOISOMERASES, TYPE I; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; RECURRENCE; SEX FACTORS;

EID: 35248873324     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-007-0253-6     Document Type: Article

References (38)

1. Berney DM, Shamash J, Gaffney J, Jordan S, Oliver RT (2002) DNA topoisomerase I and II expression in drug resistant germ cell tumours. Br J Cancer 87:624-629
2. Boonsong A, Curran S, McKay JA, Cassidy J, Murray GI, McLeod HL (2002) Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases. Hum Pathol 33:1114-1119
3. Bronstein IB, Vorobyev S, Timofeev A, Jolles CJ, Alder SL, Holden JA (1996) Elevation of DNA topoisomerase I catalytic activity and immunoprotein in human malignancies. Oncol Res 8:17-25
4. Burden DA, Osheroff N (1998) Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim Biophys Acta 1400:139-154
5. Champoux JJ (2001) DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 70:369-413
6. Coleman LW, Perkins SL, Bronstein IB, Holden JA (2000) Expression of DNA toposiomerase I and DNA topoisomerase II-alpha in testicular seminomas. Hum Pathol 31:728-733
7. Coleman LW, Bronstein IB, Holden JA (2001) Immunohistochemical staining for DNA topoisomerase I, DNA topoisomerase II-alpha and p53 in gastric carcinomas. Anticancer Res 21:1167-1172
8. Coleman LW, Rohr LR, Bronstein IB, Holden JA (2002) Human DNA topoisomerase I: an anticancer drug target present in human sarcomas. Hum Pathol 33:599-607
9. Devita VT, Hellman S, Rosenberg S (2005) Cancer: principles and practice of oncology. Lippincott Williams & Wilkins, Philadelphia
10. Gibbons D, Fogt F, Kasznica J, Holden J, Nikulasson S (1997) Comparaison of topoisomerase II alpha and Ki-67 expression in uterine cervical squamous lesions. Mod Pathol 10:409-413
11. Gupta M, Fujimori A, Pommier Y (1995) Eukaryotic DNA topoisomerases I. Biochem Biophys Acta 1262:1-14
12. Guichard S, Cussac D, Hennebelle I, Bugat R, Canal P (1997) Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo. Int J Cancer 73:729-734
13. Guichard S, Hennebelle I, Bugat R, Canal P (1998) Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line. Biochem Pharmacol 55:667-676
14. Gupta D, Bronstein IB, Holden JA (2000) Expression of DNA topoisomerase I in neoplasms of the kidney: correlation with histological grade, proliferation, and patient survival. Hum Pathol 31:214-219
15. Hafian H, Venteo L, Sukhanova A, Nabiev I, Lefevre B, Pluot M (2004) Immunohistochemical study of DNA topoisomerase I, DNA topoisomerase II alpha, p53, and Ki-67 in oral preneoplastic lesions and oral squamous cell carcinomas. Hum Pathol 35:745-751
16. Heidelberger C, Chaudhuri NK, Danneberg P, Mooren D, Griesbach L, Duschinsky R, Schnitzer RJ, Pleven E, Scheiner J (1957) Fluorinated pyrimidines: a new class of tumor-inhibitory compounds. Nature 179:663-666
17. Heck MM, Hittelman WN, Earnshaw WC (1988) Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc Natl Acad Sci USA 85:1086-1090
18. Holden JA, Rahn MP, Jolles CJ, Vorobyev SV, Bronstein IB (1997) Immunohistochemical detection of DNA topoisomerase I in formalin fixed, paraffin wax embedded normal tissues and in ovarian carcinomas. Mol Pathol 50:247-253
19. Husain I, Mohler JL, Seigler HF, Besterman JM (1994) Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res 54:539-546
20. Ichikawa W, Uetake H, Nihei Z, Mastuo K, Fujita H, Yamada Y (1999) Topoisomerase I (Topo-I) expression correlates to thymidylate synthase (TS) expression in colorectal cancer (CRC). Proc Am Soc Clin Oncol 18:946 (abstract)
21. Jansen WJ, Zwart B, Hulscher ST, Giaccone G, Pinedo HM, Boven E (1997) CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants. Int J Cancer 70:335-340
22. Kellner U, Sehested M, Jensen PB, Gieseler F, Rudolph P (2002) Culprit and victim-DNA topoisomerase II. Lancet Oncol 3:235-243
23. Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M, Danenberg PV (1997) Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15:3223-3229
24. Lynch BJ, Komaromy-Hiller G, Bronstein IB, Holden JA (1998) Expression of DNA topoisomerase I, DNA topoisomerase II-alpha, and p53 in metastatic malignant melanoma. Hum Pathol 29:1240-1245
25. Lynch BJ, Bronstein IB, Holden JA (2001) Elevations of DNA topoisomerase I in invasive carcinoma of the breast. Breast J 7:176-180
26. Merino A, Madden KR, Lane WS, Champoux JJ, Reinberg D (1993) DNA topoisomerase I is involved in both repression and activation of transcription. Nature 365:227-232
27. Monnin KA, Bronstein IB, Gaffney DK, Holden JA (1999) Elevations of DNA topoisomerase I in transitional cell carcinoma of the urinary bladder: correlation with DNA topoisomerase II-alpha and p53 expression. Hum Pathol 30:384-391
28. Nakopoulou L, Zervas A, Lazaris AC, Constantinides C, Stravodimos C, Davaris P, Dimopoulos C (2001) Predictive value of topoisomerase IIα immunostaining in urothelial bladder carcinoma. J Clin Pathol 54:309-313
29. Paradiso A, Xu J, Mangia A, Chiriatti A, Simone G, Zito A, Montemurro S, Giuliani F, Maiello E, Colucci G (2004) Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients. Int J Cancer 111:252-258
30. Pommier Y, Pourquier P, Fan Y, Strumberg D (1998) Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta 1400:83-105
31. Stewart L, Redinbo MR, Qiu X, Hol WG, Champoux JJ (1998) A model for the mechanism of human topoisomerase I. Science 279:1534-1541
32. Saltz L, Danenberg K, Paty P, Kelsen D, Salonga D, Park JM, Danemberg P (1998) High thymidylate synthase (TS) expression does not preclude activity of CTP-11 in colorectal cancer (CRC). Proc Am Soc Clin Oncol 17:991 (abstract)
33. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905-914
34. Saltz LB, Douillard JY, Pirotta N, Alakl M, Gruia G, Awad L, Elfring GL, Locker PK, Miller LL (2001) Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. Oncologist 6:81-91
35. Sanghani SP, Quinney SK, Fredenburg TB, Sun Z, Davis WI, Murry DJ, Cummings OW, Seitz DE, Bosron WF (2003) Carboxylesterases expressed in human colon tumor tissue and their role in CPT-11 hydrolysis. Clin Cancer Res 9:4983-4991
36. Staley BE, Samowitz WS, Bronstein IB, Holden JA (1999) Expression of DNA topoisomerase I and DNA topoisomerase II-αlpha in carcinoma of colon. Mod Pathol 12:356-361
37. Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S, Rustum YM (2001) Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol 19:1501-1518
38. Waters J, Cunningham D (2001) The changing face of chemotherapy in colorectal cancer. Br J Cancer 84:1-7